Lacosamide as an Adjunctive Therapy in Drug-Resistant Absence Epilepsy: Successful Treatment of Four Patients
Iranian Journal of Child Neurology,
Vol. 18 No. 4 (2024),
29 Mehr 2024
,
Page 121-126
https://doi.org/10.22037/ijcn.v18i4.45400
Abstract
Absence epilepsy is one of the most common epileptic syndromes in children, and despite its benign nature, a percentage of these children are drug-resistant. This study presents four cases of drug-resistant absence epilepsy in children who were unresponsive to traditional antiepileptic drugs. The study reports the successful use of Lacosamide as an adjunctive therapy to completely control symptoms and electroencephalogram (EEG) abnormalities. The patients, aged four to ten years, had previously failed treatment with Ethosuximide, Sodium Valproate, Levetiracetam, and Topiramate in various combinations. Lacosamide was initiated at a dose of 10 mg/kg per day in combination with Sodium valproate, resulting in rapid and sustained improvement. The patients remained symptom-free and showed no EEG abnormalities for one to two years. These findings suggest that Lacosamide can be considered a safe add-on drug for refractory absence epilepsy. However, it may be contended that additional confirmatory trials are necessary to investigate the effects of Lacosamide in a larger patient population
- lacosamide
- Adjunctive therapy
- Refractory
- Absence Epilepsy
- Children
How to Cite
References
Franzoni E, Matricardi S, Di Pisa V, Capovilla G, Romeo A, Tozzi E, Pruna D, Salerno GG, Zamponi N, Accorsi P et al: Refractory absence seizures: An Italian multicenter retrospective study. Eur J Paediatr Neurol 2015, 19(6):660-664.
Kessler SK, McGinnis E: A Practical Guide to Treatment of Childhood Absence Epilepsy. Paediatr Drugs 2019, 21(1):15-24.
Höfler J, Trinka E: Lacosamide as a new treatment option in status epilepticus. Epilepsia 2013, 54(3):393-404.
Höfler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E: Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia 2011, 52(10):e148-152.
Zawar I, Franic L, Knight EP: Response to lacosamide monotherapy in a patient with medically refractory Jeavons syndrome: a case report and review of the literature. Epileptic Disord 2020, 22(5):643-647.
Papacostas SS: Status epilepticus developing during lacosamide monotherapy. BMJ Case Rep 2015, 2015.
Ben-Menachem E, Grebe HP, Terada K, Jensen L, Li T, De Backer M, Steiniger-Brach B, Gasalla T, Brock M, Biton V: Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. Epilepsia 2019, 60(12):2437-2447.
Catterall WA, Swanson TM: Structural Basis for Pharmacology of Voltage-Gated Sodium and Calcium Channels. Mol Pharmacol 2015, 88(1):141-150.
Vossler DG, Knake S, O'Brien TJ, Watanabe M, Brock M, Steiniger-Brach B, Williams P, Roebling R: Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial. J Neurol Neurosurg Psychiatry 2020, 91(10):1067-1075.
Ákos Szabó C, Morgan LC, Sonnenberg S, Karkar KM: Absence status induced by lacosamide adjunctive therapy. Epileptic Disord 2019, 21(1):97-101.
Li J, Sun M, Wang X: The adverse-effect profile of lacosamide. Expert Opin Drug Saf 2020, 19(2):131-138.
Lancman ME, Fertig EJ, Trobliger RW, Perrine K, Myers L, Iyengar SS, Malik M: The effects of lacosamide on cognition, quality-of-life measures, and quality of life in patients with refractory partial epilepsy. Epilepsy Behav 2016, 61:27-33.
- Abstract Viewed: 506 times